{"id":"augmenting-antidepressant-aripiprazole","safety":{"commonSideEffects":[{"rate":null,"effect":"Akathisia"},{"rate":null,"effect":"Weight gain"},{"rate":null,"effect":"Sedation"},{"rate":null,"effect":"Tremor"},{"rate":null,"effect":"Nausea"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Aripiprazole is added to ongoing antidepressant treatment to improve efficacy in patients with inadequate response to antidepressants alone. As a partial dopamine D2 agonist and serotonin modulator, it complements the mechanism of SSRIs/SNRIs by stabilizing dopaminergic and serotonergic signaling. This combination strategy targets multiple neurotransmitter systems implicated in major depressive disorder.","oneSentence":"Aripiprazole augments antidepressant therapy by acting as a partial agonist at dopamine D2 and serotonin 5-HT1A receptors, enhancing monoaminergic neurotransmission in depression.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:03:05.960Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Major depressive disorder with inadequate response to antidepressant monotherapy"}]},"trialDetails":[{"nctId":"NCT01421342","phase":"PHASE3","title":"VA Augmentation and Switching Treatments for Improving Depression Outcomes","status":"COMPLETED","sponsor":"VA Office of Research and Development","startDate":"2012-12","conditions":"Major Depressive Disorder","enrollment":1522},{"nctId":"NCT00220636","phase":"PHASE4","title":"Abilify as an Adjunctive Treatment for Refractory Depression","status":"COMPLETED","sponsor":"St. Luke's-Roosevelt Hospital Center","startDate":"2005-03","conditions":"Depressive Disorder, Major","enrollment":15}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":1,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Augmenting: Antidepressant + Aripiprazole","genericName":"Augmenting: Antidepressant + Aripiprazole","companyName":"VA Office of Research and Development","companyId":"va-office-of-research-and-development","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Aripiprazole augments antidepressant therapy by acting as a partial agonist at dopamine D2 and serotonin 5-HT1A receptors, enhancing monoaminergic neurotransmission in depression. Used for Major depressive disorder with inadequate response to antidepressant monotherapy.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}